

24. **(New)** A composition comprising the polypeptide of any one of claims 7 to 11 and 20 and a pharmaceutically acceptable carrier.

25. **(New)** A method for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition of claim 24.

26. **(New)** A method for detecting the presence of a polypeptide of claim 18 in a sample comprising:

- a) contacting the sample with a compound which selectively binds to the polypeptide; and
- b) determining whether the compound binds to the polypeptide in the sample to thereby detect the presence of a polypeptide of claim 18 in the sample.

REMARKS

Claims 1-6 were pending in the application. Claims 1-6 have been cancelled and claims 7-26 have been added. Accordingly, claims 7-26 will be pending upon entry of the instant amendments presented herein.

Support for the amendments to claims 7-26 may be found in the claims as originally filed and throughout the specification. In particular, support for claim 7 can be found in the specification at least at page 5, lines 13-17; support for claim 8 can be found in the specification at least at page 11, lines 4-9; support for claim 9 can be found in the specification at least at page 5, lines 13-17; support for claim 10 can be found in the specification at least at page 10, lines 7-12; support for claim 11 can be found in the specification at least at page 7, lines 15-18; support for claim 12 can be found in the specification at least at page 66, lines 6-9; support for claim 13 can be found in the specification at least at page 66, lines 4-5; support for claim 14 can be found in the specification at least at page 63, line 24 to page 64, line 12; support for claim 15 can be

support for claim 17 can be found in the specification at least at page 5, lines 13-22;
support for claim 18 can be found in the specification at least at page 5, lines 17-22;
support for claim 19 can be found in the specification at least at page 5, line 23 to page 7,
line 4; support for claim 20 can be found in the specification at least at page 7, lines 15-
18 and at page 10, lines 7-12; support for claim 21 can be found in the specification at
least at page 7, lines 15-18; support for claim 22 can be found in the specification at least
at page 63, line 24 to page 64, line 12; support for claim 23 can be found in the
specification at least at page 11, line 22 to page 12, line 13; support for claim 24 can be
found in the specification at least at page 62, lines 3-7; support for claim 25 can be found
in the specification at least at page 62, lines 3-7; and support for claim 26 can be found in
the specification at least at page 12, line 21 to page 31, line 20. Amendment or
cancellation of the claims should in no way be construed as an acquiescence to any of the
Examiner's rejections and was done solely to expedite prosecution. Applicants reserve
the right to pursue the claims as originally filed in this or a separate application(s).

ELECTION / RESTRICTION

The Examiner has required restriction to one of the following inventions under 35
U.S.C. §§121 and 372:

- I. Groups 1-10, claim(s) 1-6, in part, drawn to one of 10 proteins comprising
an amino acid sequence (SEQ ID NOs: 1-10).
- II. Groups 11-30, claim(s) 1-6, in part, drawn to one of 20 cDNA molecules
(SEQ ID NOs: 11-20, 21, 23, 25, 27, 29, 31, 33, 35, 36, 39) coding for a


Applicants hereby elect, without traverse, to prosecute the invention of **Group 1** (SEQ ID NO:1) and **Group 11** (SEQ ID NO:11). Applicants reserve the right to pursue the non-elected subject matter of the nucleic acids or proteins in one or more divisional applications.

CONCLUSION

If a telephone conversation with Applicants' Attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


 Cynthia L. Kanik, Esq.
 Registration No. 37,320
 Attorney for Applicants

28 State Street
 Boston, MA 02109
 (617) 227-7400

Dated: June 19, 2001